Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment

Marie Wijk, Paolo Denti, Kamunkhwala Gausi, Bronwyn Myers, Tara Carney, Laura F. White, Danie Theron, Charles Parry, C. Robert Horsburgh, Noorjahn Rawoot, Robin M. Warren, Richard Court, Sanjana G. Kulkarni, Maha Farhat, C. Buys, Samantha Malatesta, Sarah E Weber, Suchitra Kulkarni, Helen McIlleron, Karen R. Jacobson, Frank KloproggeClinical 2025 · DOI

Abstract

Our findings highlight the role of rifampicin plasma exposure in optimizing bacillary clearance and improving treatment outcomes, even within standard dosing regimens for drug-susceptible tuberculosis.
BibTeX
@inproceedings{wijk2025insights,
  author = {Marie Wijk and Paolo Denti and Kamunkhwala Gausi and Bronwyn Myers and Tara Carney and Laura F. White and Danie Theron and Charles Parry and C. Robert Horsburgh and Noorjahn Rawoot and Robin M. Warren and Richard Court and Sanjana G. Kulkarni and Maha Farhat and C. Buys and Samantha Malatesta and Sarah E Weber and Suchitra Kulkarni and Helen McIlleron and Karen R. Jacobson and Frank Kloprogge},
  title = {{Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1093/cid/ciaf586},
}

Loading related content...

Figure